Nutriband (NTRB) AI Stock Analysis

• Market Cap: $95.15M
• Dividend Yield: N/A
• Average Volume (3M): 103.80K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.50
• Revenue Growth: 18.92%
• EPS Growth: -17.30%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.98
• Shares Outstanding: 11,154,171
• 10 Day Avg. Volume: 43,195
• 30 Day Avg. Volume: 103,798
• PEG Ratio: -0.99
• Price to Book (P/B): 17.55
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -17.22
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 10.46
• Enterprise Value/Gross Profit: 110.96
• Enterprise Value/Ebitda: -2.63
• 1Y Price Target: $15.00
• Price Target Upside: 75.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 57 Neutral
• Price Target: $8.50 ▼(-0.35%Downside)

Nutriband's overall score reflects its financial challenges, with persistent losses and negative cash flows being significant concerns. However, the technical indicators suggest a positive short-term trend, and recent corporate actions could enhance shareholder value. The stock's valuation is currently unattractive due to negative earnings.

Positive Factors

Market Potential

Analysts believe that AVERSA Fentanyl can be the first abuse-deterrent transdermal fentanyl patch, potentially capturing market share from existing generic patches.

Partnerships

Nutriband's partnership with Kindeva Drug Delivery to integrate AVERSA technology into transdermal fentanyl patches could significantly enhance product safety.

Product Development

The AVERSA Fentanyl patch's abuse-deterrent features could potentially allow for decreased restrictions and improve access for patients with severe chronic pain.

Negative Factors

Regulatory Approval

The success of the Phase 1 clinical trial is crucial for Nutriband to proceed with a New Drug Application using the 505(b)(2) pathway, presenting a potential regulatory hurdle.

Nutriband Business Overview & Revenue Model

Company Description

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

How the Company Makes Money

Nutriband makes money through the development, manufacture, and sale of its transdermal delivery products. The company generates revenue by selling its pharmaceutical delivery systems to healthcare providers, pharmaceutical companies, and distributors. Key revenue streams include the sale of its proprietary transdermal patches, licensing agreements for its drug delivery technology, and partnerships with other pharmaceutical companies to develop and commercialize new transdermal products. Additionally, Nutriband may receive milestone payments and royalties from partnerships and licensing deals, contributing to its earnings.

Nutriband Financial Statement Overview

Summary

Nutriband faces significant challenges in improving profitability and cash flow while maintaining a stable financial position. Despite some revenue growth, persistent losses and negative cash flows remain critical issues. The balance sheet is a strong point with low leverage, but ongoing losses and reliance on external financing could pose risks.

Income Statement

Nutriband has shown modest revenue growth over the years, but profitability remains a challenge with consistently negative EBIT and net income margins. Revenue increased by 2.6% from 2024 to 2025, indicating slow growth. However, the gross profit margin has been volatile, and the net profit margin remains deeply negative, reflecting the company's difficulty in managing costs in relation to revenues.

Balance Sheet

The balance sheet is relatively stable, with a low debt-to-equity ratio indicating conservative leverage. Stockholders' equity remains strong at approximately 86% of total assets. However, the company's return on equity is negative due to ongoing net losses, which could be concerning for long-term sustainability.

Cash Flow

Nutriband's cash flow situation is challenging, with negative operating and free cash flows reflecting ongoing operational losses. The operating cash flow to net income ratio is negative, indicating cash outflows exceed net losses. The company relies heavily on financing cash flows to offset operating cash deficits, which is not sustainable long-term.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.14M	2.09M	2.08M	1.42M	943.70K
Gross Profit	699.30K	862.11K	750.41K	504.31K	361.32K
EBITDA	-10.18M	-5.12M	-4.11M	-5.74M	-2.48M
Net Income	-10.48M	-5.49M	-4.81M	-8.42M	-3.21M
Balance Sheet
Total Assets	7.47M	7.52M	9.46M	12.74M	9.93M
Cash, Cash Equivalents and Short-Term Investments	4.31M	492.94K	1.99M	4.89M	151.99K
Total Debt	186.35K	241.28K	185.81K	134.57K	1.79M
Total Liabilities	1.04M	1.08M	883.39K	880.38K	2.82M
Stockholders Equity	6.43M	6.44M	8.57M	11.86M	7.11M
Cash Flow
Free Cash Flow	-4.72M	-3.58M	-3.07M	-2.89M	-297.06K
Operating Cash Flow	-4.63M	-3.53M	-2.99M	-2.81M	-297.06K
Investing Cash Flow	-92.04K	-51.76K	-79.30K	-81.59K	66.99K
Financing Cash Flow	8.54M	2.09M	160.07K	7.63M	371.87K

Nutriband Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.53
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTRB, the sentiment is Positive. The current price of 8.53 is above the 20-day moving average (MA) of 8.42, above the 50-day MA of 7.54, and above the 200-day MA of 6.26, indicating a bullish trend. The MACD of 0.24 indicates Positive momentum. The RSI at 55.11 is Neutral, neither overbought nor oversold. The STOCH value of 65.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NTRB.

Nutriband Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$16.95B	5.65	-7.44%	2.90%	11.55%	-28.15%
NTRB	57 Neutral	$95.15M	―	-108.02%	―	18.92%	-17.30%
DOMH	―	$74.83M	―	-92.68%	―	―	―
AVTX	54 Neutral	$72.44M	―	678.24%	―	-69.59%	―
SER	47 Neutral	$53.82M	―	45.59%	―	34.04%	55.34%
CBUS	44 Neutral	$80.66M	―	-157.73%	―	104.78%	40.41%
ANRO	42 Neutral	$83.38M	―	-38.04%	―	―	―

Nutriband Corporate Events

Nutriband Approves New Series A Preferred Stock

On July 9, 2025, Nutriband Inc.’s Board of Directors approved an amendment to its Articles of Incorporation to authorize a new series of non-voting shares, the Series A Convertible Preferred Stock. This amendment allows for the issuance of 2,788,678 shares of Series A Preferred Stock, which can be converted into common stock following FDA approval of the company’s transdermal products. The company also announced a preferred stock dividend, with one share of Series A Preferred stock issued for every four shares of common stock held, with a record date of July 25, 2025. This move could potentially enhance shareholder value and position the company favorably in the market.

The most recent analyst rating on (NTRB) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Nutriband stock, see the NTRB Stock Forecast page.